1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Alembic Limited

Alembic Limited

86.73
INR
-3.55
(-3.93%)
12.48EPS
7.34P/E
23.52BMarket Cap
Alembic Limited
NSE:ALEMBICLTD
(National Stock Exchange of India)

Recent

price

86.73

P/E

ratio

7.34

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
INR
31.88
4.52
6.71
5.75
5.39
4.62
5.04
4.47
4.53
2.62
2.64
2.78
4.61
5.73
8.22
8.96
9.3
Revenue per Share
2.26
-0.46
0.43
1.11
3.99
8.78
5.44
6.1
8.26
12.82
13.35
8.65
7.42
10.46
12.1
12.36
12.48
Basic EPS, GAAP
0.86
-2.37
2.89
-0.41
0.81
0.35
1.4
-0.03
-0.07
-0.62
-1.93
-2.09
0.51
-1.31
1.39
1.69
- -
Free Cash Flow per Basic Share
0.18
0.81
0.01
0.12
0.18
0.19
0.18
0.18
0.25
0.24
0.59
0.2
1.79
2.19
2.38
2.39
- -
Dividend per Share
11.11
7.38
7.71
8.64
21.82
30.08
34.13
42.28
47.06
55.22
89.45
97.23
80.93
85.11
91.07
95.22
- -
Book Value per Share
11.11
7.38
7.71
8.64
21.82
30.08
34.13
42.28
47.06
55.22
89.45
97.22
80.92
85.11
91.07
95.22
- -
Tangible Book Value per Share
377
267
267
267
267
267
267
267
258
257
257
257
257
257
257
257
257
Basic Weighted Avg Shares
12,020
1,208
1,792
1,536
1,439
1,233
1,346
1,195
1,169
673
678
714
1,183
1,471
2,112
2,300
2,390
Sales/Revenue/Turnover
10.95
-9.84
9.01
13.63
15.84
0.2
1.24
6.13
13.21
0.28
14.22
12.7
28.4
33.32
39.34
34.1
30.66
Operating Margin (%)
296
109
99
80
61
62
51
38
27
32
39
49
67
78
106
124
131
Depreciation Expense
854
-122
115
295
1,066
2,345
1,454
1,630
2,131
3,291
3,428
2,221
1,906
2,686
3,107
3,174
3,206
Net Income, GAAP
20.08
- -
- -
11.77
- -
2.4
- -
5.42
8.04
0.14
18.78
11.92
7.12
9.56
7.03
15.34
15.36
Effective Tax Rate (%)
7.1
-10.1
6.41
19.22
74.05
190.19
108.04
136.4
182.32
489.36
505.39
311.14
161.1
182.58
147.11
138.01
134.17
Profit Margin (%)
1,392
69
220
636
787
1,115
1,229
1,276
500
1,170
427
756
883
471
944
959
- -
Working Capital
1,285
949
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
74
107
66
- -
LT Debt
2,967
1,972
2,058
2,307
5,826
8,031
9,114
10,858
12,085
14,180
22,970
24,966
20,780
21,856
23,386
24,451
- -
Total Equity
15.71
- -
- -
7.65
- -
-0.31
- -
1
1.18
0.04
0.32
0.42
0.98
2.08
3.52
2.75
- -
Return on Invested Capital (%)
16.13
- -
- -
13.69
- -
33.86
- -
16.32
18.58
25.08
18.47
9.28
8.35
12.62
13.76
13.28
- -
Return on Capital (%)
27.88
-4.94
5.7
13.53
26.22
33.85
16.96
16.32
18.58
25.06
18.46
9.26
8.34
12.6
13.73
13.27
- -
Return on Common Equity (%)

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
40
- -
LT Borrowings
- -
66
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
257
257
257
Market Capitalization
25,984
18,206
23,516

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
1,972
- -
Cash, Cash Equivalents & STI
- -
984
- -
Accounts Receivable, Net
- -
319
- -
Inventories
- -
522
- -
Total Current Liabilities
- -
1,013
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
40
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
13.19%
1.73%
4.55%
Free Cash Flow
62.42%
-131.65%
21.93%
Net Income, GAAP
7.28%
1.87%
2.16%
Sales/Revenue/Turnover
10.19%
29.56%
8.9%
Total Cash Common Dividend
92.94%
151.38%
0.4%

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
508
529
579
603
2,112
2026
498
559
743
600
2,300
2027
487
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
2.17
4.71
2.55
2.67
12.1
2026
2.4
5
2.34
2.61
12.36
2027
2.53
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
2.38
2026
- -
- -
- -
- -
2.39
2027
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Alembic Limited engages in the manufacturing and marketing of fermentation and chemistry based active pharmaceutical ingredients (APIs) as well as real estate development in India. The company manufactures and sells APIs through its pharmaceutical segment; develops and constructs residential and commercial real estate projects; provides project management and marketing consultancy services; leases commercial properties; and operates co-generation power plants with 11 MW capacity and wind power plants with 5 MW capacity, exporting certain products internationally. Founded in 1907 and headquartered in Vadodara, Gujarat, India, Alembic Limited operates primarily in India and serves domestic and global markets as a subsidiary of Nirayu Limited. In recent developments, the real estate segment experiences strong growth from FY23 to FY24 driven by high demand and elevated property prices; the company maintains ongoing board changes including reappointments of independent directors and completion of director terms in 2025; and it continues strategic investor communications through regular financial disclosures and compliance updates as of late 2025.